LEO Pharma

LEO Pharma A/S appoints Brian Hilberdink new President of LEO Pharma Inc. United States


Ballerup, February 17, 2022 – LEO Pharma today announced it has appointed Brian Hilberdink new EVP and President of LEO Pharma Inc., in the United States, effective March 14, 2022. Brian Hilberdink joins LEO Pharma from Novo Nordisk, Inc., in the U.S. where he served as Senior Vice President of Sales.

“We are excited to soon have an accomplished executive like Brian Hilberdink with more than 25 years of global experience developing and executing strategy leading our U.S. operation. With the recent FDA approval of our first biologic, and Brian at the helm, LEO Pharma stands to strongly deliver on our growth strategy in the world’s largest pharmaceutical market, said Anders Kronborg, Acting CEO of LEO Pharma.

Prior to joining Novo Nordisk in the United States as a Senior Vice President, Brian Hilberdink served as President of Novo Nordisk Canada Inc. and Corporate Vice President in Global Marketing of Novo Nordisk A/S in Denmark. In that role, he led the launch of the company’s next generation insulin portfolio.

“LEO Pharma has an exciting future, and I am thrilled to have the opportunity to lead the company’s growth journey in the U.S. Joining a company with such a history, which is going through a remarkable transformation and also expecting to go public feels like joining a 100-year-old start-up. It is a once in a lifetime opportunity that I wouldn’t miss, said Brian Hilberdink.

Brian Hilberdink holds a bachelor’s degree from the Arts & Science faculty at Queen’s University in Canada and has completed extensive executive education at multiple universities.


David Patti
+1 973 796 7706

Henrik Heskjær
+45 3140 6180


About LEO Pharma

LEO Pharma
LEO Pharma
Industriparken 55
2750 Ballerup

4494 5888http://www.leo-pharma.com/

About LEO Pharma

LEO Pharma helps people achieve healthy skin. The company is a leader in medical dermatology with a robust R&D pipeline, a wide range of therapies and a pioneering spirit. Founded in 1908 and majority owned by the LEO Foundation, LEO Pharma has devoted decades of research and development to advance the science of dermatology, setting new standards of care for people with skin conditions. LEO Pharma is headquartered in Denmark with a global team of 6,000 people, serving 93 million patients in 130 countries. In 2020, the company generated net sales of DKK 10.133 billion.

Subscribe to releases from LEO Pharma

Subscribe to all the latest releases from LEO Pharma by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from LEO Pharma

LEO Pharma announces positive phase 3 topline results from DELTA 1 trial with delgocitinib cream in adults with moderate to severe chronic hand eczema (CHE)6.12.2022 08:00:00 CET | Press release

• The first phase 3 clinical trial (DELTA 1) with delgocitinib cream in adults with moderate to severe chronic hand eczema (CHE) met primary and all key secondary endpoints • DELTA 1 trial results show that delgocitinib cream provided early symptom-relief in a hard-to-treat disease • The majority of adverse events observed were non-serious, mild or moderate in severity, and not considered treatment related


• In partnership with Global patient advocate Ashley Ann Lora, AD Days Around the World explores the impact of atopic dermatitis (AD) on the lives of individuals around the world living with this chronic and debilitating skin disease • The campaign features the emotional journey of four patient advocates from France, Italy, Germany and Spain and showcases the impact that AD has on people, regardless of culture or geography

LEO Pharma and DKSH Partner to Deliver Products and Solutions to People in Asia with Skin Conditions and Thrombosis29.9.2022 07:00:00 CEST | Press release

LEO Pharma and DKSH have entered into an agreement to bring high-quality therapeutic products for dermatology and thrombosis to patients across Asia. This agreement both supports LEO Pharma’s strategy of building a simpler and more competitive organization and DKSH Business Unit Healthcare’s strategic focus of strengthening its regional footprint.

LEO Pharma presents new Adtralza® safety data in moderate-to-severe atopic dermatitis at the 31st EADV Congress8.9.2022 14:15:00 CEST | Press release

• An interim safety analysis from ECZTEND, an open-label, 5-year extension trial, demonstrated consistent safety from the parent trials for up to 3.5 years of Adtralza® (tralokinumab) treatment in adult patients with moderate-to-severe atopic dermatitis.1 • Exposure-adjusted incidence rates of adverse events of special interest, including conjunctivitis, eczema herpeticum, and skin infections requiring systemic treatment, were generally lower than rates reported during the placebo-controlled period up to Week 16 and declined over time.1

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom